-
-
公开(公告)号：KR101844479B1
公开(公告)日：2018-04-03
申请号：KR1020110120317
申请日：2011-11-17
Applicant: 삼성전자주식회사
IPC: C07K16/28 , C12N15/13 , A61K39/395 , A61P17/02
CPC classification number: C07K16/40 , C07K16/2863 , C07K2317/21 , C07K2317/33 , C07K2317/74 , C07K2317/75 , C07K2317/92
Abstract: 항 c-Met 항체또는그의항원결합단편및 이를포함하는상처치료또는조직재생용약학적조성물및 세포증식촉진용조성물에관한것이다. 일구체예에따른항 c-Met 항체또는그의항원결합단편및 이를포함하는약학적조성물에의하면, 세포이동을증진시켜상처치료또는조직재생에효율적으로사용될수 있으며, 세포증식을효율적으로촉진시킬수 있다.
-
公开(公告)号：KR1020150028652A
公开(公告)日：2015-03-16
申请号：KR1020130107568
申请日：2013-09-06
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61K48/00 , A61P35/00
CPC classification number: A61K39/39558 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/519 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/74 , C12N15/113 , C12N2310/14 , C12N2320/31 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition for combination therapy for preventing and/or treating cancer comprising a c-Met inhibitor and a beta-catenin inhibitor as active ingredients, to use of c-Met inhibitor efficacy enhancement by the beta-catenin inhibitor, and use of beta-catenin inhibitor efficacy enhancement by the c-Met inhibitor. The combination therapy of the c-Met inhibitor and beta-catenin inhibitor enables treatment of diseases which could not be treated by the c-Met inhibitor alone, thereby extending indications and overcoming resistance against the c-Met inhibitor.
Abstract translation: 本发明涉及一种用于预防和/或治疗癌症的组合治疗药物组合物，其包含c-Met抑制剂和β-连环蛋白抑制剂作为活性成分，以使用由β-连环蛋白抑制剂提高c-Met抑制剂功效， 并通过c-Met抑制剂使用β-连环蛋白抑制剂的功效增强。 c-Met抑制剂和β-连环蛋白抑制剂的联合治疗能够治疗单独用c-Met抑制剂治疗的疾病，从而延长适应症并克服对c-Met抑制剂的抵抗力。
-
公开(公告)号：KR1020140120572A
公开(公告)日：2014-10-14
申请号：KR1020130036506
申请日：2013-04-03
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61P35/00 , A61P3/00
CPC classification number: C07K16/2863 , A61K2039/507 , C07K16/22 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to a pharmaceutical composition for coadministration to prevent and treat angiogenesis-related diseases containing an anti-c-Met antibody and an anti-Ang2 antibody. By coadministration of the anti-c-Met antibody and the anti-Ang2 antibody provided in the present invention, improved treatment is possible though effects of inhibiting growth of cancer cells and angiogenesis. Accordingly, excellent synergy treatment effect can be expected in various angiogenesis diseases which can′t obtain treatment effect or show little effect only for administration of an existing antibody.
Abstract translation: 本发明涉及共同给药以预防和治疗含有抗c-Met抗体和抗Ang2抗体的血管发生相关疾病的药物组合物。 通过本发明提供的抗c-Met抗体和抗Ang2抗体的共同给药，可以通过抑制癌细胞生长和血管发生的作用来改善治疗。 因此，对于不能获得治疗效果的多种血管生成疾病或仅对现有抗体的给药几乎没有影响，可以预期出色的协同治疗效果。
-
公开(公告)号：KR1020140119661A
公开(公告)日：2014-10-10
申请号：KR1020140038839
申请日：2014-04-01
Applicant: 삼성전자주식회사
IPC: A61K39/395 , C07K16/28 , A61P35/00
CPC classification number: A61K39/39558 , A61K31/4412 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92 , A61K2300/00
Abstract: Provided is a pharmaceutical composition containing anti-c-Met antibody and sorafenib as active ingredients for a combination therapy for preventing and/or treating cancer diseases. The pharmaceutical composition for a combination therapy has an excellent synergistic effect and can reduce the effective dose of the anti-c-Met antibody, thereby can more effectively treat the cancer.
Abstract translation: 提供含有抗c-Met抗体和索拉非尼作为预防和/或治疗癌症疾病的组合疗法的活性成分的药物组合物。 用于联合治疗的药物组合物具有优异的协同效应，并且可以降低抗c-Met抗体的有效剂量，从而可以更有效地治疗癌症。
-
Patent Agency Ranking
公开(公告)号：KR1020140119623A
公开(公告)日：2014-10-10
申请号：KR1020130161685
申请日：2013-12-23
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61P35/00
CPC classification number: A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2300/00
Abstract: Provided is a pharmaceutical composition containing anti-c-Met antibody and FGFR inhibitor as active ingredients for a combination therapy for preventing and/or treating cancer diseases. The pharmaceutical composition for a combination therapy has an excellent synergistic effect and can reduce the effective dose of the anti-c-Met antibody, thereby can more effectively treat the cancer.
Abstract translation: 提供含有抗c-Met抗体和FGFR抑制剂作为预防和/或治疗癌症疾病的组合疗法的有效成分的药物组合物。 用于联合治疗的药物组合物具有优异的协同效应，并且可以降低抗c-Met抗体的有效剂量，从而可以更有效地治疗癌症。
-
27.发明公开
公开(公告)号：KR1020140118798A
公开(公告)日：2014-10-08
申请号：KR1020140033084
申请日：2014-03-21
Applicant: 삼성전자주식회사
Abstract: The present invention provides: a composition for testing effects of a c-Met antibody including a gene marker; and a method for testing effects of a c-Met antibody using the same gene marker. The composition includes one or more selected from a group consisting of a TNFRSF21 (Tumor necrosis factor receptor superfamily, member 21) gene, a CASP10 (Caspase 10) gene, a TP53 (Tumor protein p53) gene, a BCL2 (B-cell CLL/lymphoma 2) gene, a BCL2L1 (BCL2-like 1) gene, and protein encoded by the same genes. According to the present invention, an antibody with high efficacy can be quickly screened.
Abstract translation: 本发明提供：用于检测包含基因标记物的c-Met抗体的效果的组合物; 以及使用相同基因标记物测试c-Met抗体的作用的方法。 该组合物包含选自TNFRSF21（肿瘤坏死因子受体超家族，成员21）基因，CASP10（Caspase 10）基因，TP53（肿瘤蛋白p53）基因，BCL2（B细胞CLL） /淋巴瘤2）基因，BCL2L1（BCL2样1）基因和由相同基因编码的蛋白质。 根据本发明，可以快速筛选出具有高效力的抗体。
-
公开(公告)号：KR1020140097607A
公开(公告)日：2014-08-06
申请号：KR1020130009907
申请日：2013-01-29
Applicant: 삼성전자주식회사
IPC: A61K38/18 , A61K39/395 , A61K47/48 , C07K14/475
CPC classification number: A61K31/496 , A61K31/122 , A61K31/497 , A61K39/39558 , A61K45/06 , C07K16/2863 , A61K38/18 , A61K39/395 , A61K47/50 , C07K14/475 , A61K2300/00
Abstract: Provided is a pharmaceutical composition for a combination therapy containing a p53 activator and a c-Met inhibitor as an active component. The pharmaceutical composition for the combination therapy expresses excellent synergistic effects and reduces an effective does of the p53 activator and the c-Met inhibitor, thereby enabling efficient treatment.
Abstract translation: 本发明提供含有p53激活剂和c-Met抑制剂作为活性成分的联合疗法的药物组合物。 用于联合治疗的药物组合物表现出优异的协同效应，并且降低了p53激活剂和c-Met抑制剂的有效作用，从而使得能够进行有效的治疗。
-
公开(公告)号：KR1020140035266A
公开(公告)日：2014-03-21
申请号：KR1020130108913
申请日：2013-09-11
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61K47/48 , A61P35/00
CPC classification number: A61K39/3955 , A61K45/06 , C07K16/2863 , C07K2317/24
Abstract: Provided is a pharmaceutical composition for a combination therapy which contains an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof as an active ingredient for preventing and/or treating c-Met and angiogenic factor induced diseases. The pharmaceutical composition for the combination therapy has a superior synergistic effect, thereby more effective treatments are available.
Abstract translation: 提供了含有血管生成抑制剂和抗c-Met抗体或其抗原结合片段作为预防和/或治疗c-Met和血管生成因子诱导的疾病的活性成分的药物组合物。 用于联合治疗的药物组合物具有优异的协同效应，从而可获得更有效的治疗。
-
公开(公告)号：KR1020130036992A
公开(公告)日：2013-04-15
申请号：KR1020110101291
申请日：2011-10-05
Applicant: 삼성전자주식회사
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61P35/00
CPC classification number: A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: PURPOSE: An anti-c-Met humanized antibody and use thereof are provided to efficiently prevent and treat cancer. CONSTITUTION: Anti-c-Met humanized antibody comprises a medium variable region consisting of amino acid sequence of sequence number 1 and a light variable region consisting of amino acid sequence of sequence number 2. The light variable region comprises a medium variable domain comprised of amino acid sequence of sequence number 3 and amino acid sequence of sequence number 4.
Abstract translation: 目的：提供抗c-Met人源化抗体及其用途，以有效预防和治疗癌症。 构成：抗c-Met人源化抗体包含由序列号1的氨基酸序列组成的中等可变区和由序列号2的氨基酸序列组成的轻度可变区。轻度可变区包含由氨基 序列号3的酸序列和序列号4的氨基酸序列。
-
-
-
-
-
-
-
-
-
Search Results
75
records
(took 0.056 seconds)
